Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
By J. Ko, A. Zea, B. Rini, J. Ireland, P. Elson, P. Cohen, A. Golshayan, P. Rayman, L. Wood, Jorge A. Garcia and 3 more. Clinical Cancer Research, 2009
870 citations recorded by the source corpus.
Purpose: Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived suppressor cells (MDSC) represent one mechanism by which tumors induce T-cell suppression. Several factors pivotal to the accumulation of MDSC are targeted by the tyrosine kinase inhibitor, sunitinib. The effect of sunitinib on MDSC-mediated immunosuppression in RCC patients has been investigated. Experimental Design: Patient peripheral blood levels of MDSC and regulatory T-cell (Treg) and T-cell production of IFN-γ were evaluated before and after sunitinib treatment. Correlations between MDSC and Treg normalization as well as T-cell production of IFN-γ were examined. The in vitro effect of sunitinib on patient MDSC was evaluated. Results: Metastatic RCC patients had elevated levels of CD33+HLA-DR− and CD15+CD14− MDSC, and these were partially overlapping populations. Treatment with sunitinib resulted in significant reduction in MDSC measured by several criteria. Sunitinib-mediated reduction in MDSC was correlated with reversal of type 1 T-cell suppression, an effect that could be reproduced by the depletion of MDSC in vitro. MDSC reduction in response to sunitinib correlated with a reversal of CD3+CD4+CD25hiFoxp3+ Treg cell elevation. No correlation existed between a change in tumor burden and a change in MDSC, Treg, or T-cell production of IFN-γ. In vitro addition of sunitinib reduced MDSC viability and suppressive effect when used at ≥1.0 μg/mL. Sunitinib did not induce MDSC maturation in vitro. Conclusions: Sunitinib-based therapy has the potential to modulate antitumor immunity by reversing MDSC-mediated tumor-induced immunosuppression.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/29e6d088ca4ff41183dacbafba932ac6debdf90e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors (2015, background): “Targeting the VEGF-A–VEGFR axis with antiangiogenic molecules could decrease T reg cell and MDSC proportions in tumor-bearing mice and cancer patients (Finke et al., 2008; Ko et al., 2009; Cao et al., 2011; Terme et al., 2013).”
- ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, neutral): “[ tumor growth delay (Gabrilovich et al., 1999) Anti-mouse VEGF mAb- anti-gp100 pmel-1 T cells, gp100 vaccine, IL-2 after lymphodepletion melanoma [ immune cell infiltration [ tumor growth delay [ survival (Shrimali et al., 2010) VEGFR-1 CAR-modified T cells lung carcinoma Y endothelial tube formati”